clinical biotechnology News
-
Cabaletta Bio Announces Appointment of Michael Gerard as General Counsel
PHILADELPHIA, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Michael Gerard has been appointed general counsel. ...
-
Destiny Pharma CEO, Neil Clark, to present at the HC Wainwright 24th Annual Global Investment Conference
Destiny Pharma plc (AIM:DEST), a clinical stage biotechnology company focused on the development of novel medicines to prevent life threatening infections, today announces that Destiny Pharma’s CEO, Neil Clark, will present virtually at the upcoming HC Wainwright 24th Annual Global Investment Conference, being held on 12-14 September 2022 in New York and virtually. The presentation will be ...
-
Micron signs new research agreement with commercial partner
ATLANTA, July 23, 2018 – Following the successful completion of a first stage of preclinical development work with one of its commercial partners, a leading clinical stage biotechnology company, Micron Biomedical, Inc. (Micron) signed a new research agreement (RA) with its partner to continue the development of a microneedle patch for delivery of the partner’s API. The new RA includes ...
-
Dr David Dantzker to present Origin’s plasma-generated Nitric Oxide to the MEIDAM dermatology conference in Dubai on September 21, 2019
Origin, Inc., a Phase III clinical-stage biotechnology company, today announced that Dr. David Dantzker, Vice Chairman and Chief Medical Officer of Origin, and former Chairman of the American Board of Internal Medicine, would be presenting Origin’s plasma-generated Nitric Oxide technology to The 4th Middle East International Dermatology & Aesthetic Medicine Conference & Exhibition ...
By Origin, Inc
-
Cabaletta Bio Reports Top-line Biologic Activity Data from Two Lowest Dose Cohorts in DesCAARTes™ Trial in Patients with Mucosal Pemphigus Vulgaris
PHILADELPHIA, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today reported top-line data on biologic activity from the two lowest dose cohorts in the DesCAARTes™ Phase 1 clinical trial of DSG3-CAART for ...
-
Cabaletta Bio Reports Clinical Data from the Second Dose Cohort in DesCAARTes™ Trial in Patients with mPV
PHILADELPHIA, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced 28-day data from the second dose cohort, at the 100 million cell dose level, in the DesCAARTes™ Phase 1 clinical trial of ...
-
Cabaletta Bio Reports Clinical Data from the Third Dose Cohort in DesCAARTes™ Trial in Patients with mPV
PHILADELPHIA, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced 28-day clinical data from the third dose cohort using 500 million DSG3-CAART cells in the DesCAARTes™ Phase 1 clinical trial ...
-
Celyad Oncology to Present at the H.C. Wainwright Global Investment Conference
Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company plans to participate virtually at the upcoming H.C. Wainwright Global Investment Conference, May 23 ...
-
AdAlta to present at BIO International Convention
AdAlta Limited (ASX:1AD), the clinical stage biotechnology company developing novel therapeutic products from its i-body platform, is pleased to advise that CEO and Managing Director, Dr Tim Oldham, has been selected to present at the Bio International Convention in San Diego, California on Monday 13 June, US time. BIO is the world’s largest advocacy association representing member ...
-
Lipella Pharmaceuticals Announces Pricing of Initial Public Offering of Common Stock
PITTSBURGH, Dec. 19, 2022 /PRNewswire/ — Lipella Pharmaceuticals, Inc. (“Lipella,” “our, “us” or the “Company”), a clinical-stage biotechnology company focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications, today announced the pricing of its initial ...
-
U.S. Food and Drug Administration Grants Cabaletta Bio Fast Track Designation for MuSK-CAART
PHILADELPHIA, March 01, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for MuSK-CAART, or muscle-specific kinase (MuSK) chimeric ...
-
NexImmune Announces Formation of Autoimmune and Infectious Diseases Scientific Advisory Board
GAITHERSBURG, Md., Jan. 05, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced the formation of its Autoimmune and Infectious Disease Scientific Advisory Board (AI & ID SAB). The AI ...
-
AdAlta presentation at Bioshares Biotech Summit
AdAlta Limited (ASX:1AD), the clinical stage biotechnology company developing novel therapeutic products from its i-body platform, is pleased to advise that CEO and Managing Director, Dr Tim Oldham, will be presenting at the 16th Bioshares Biotech Summit in Albury, NSW on 11 May 2022. The Bioshares Biotech Summit’s unique format brings together biotechnology companies and equity capital ...
-
NexImmune to Participate in The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) Panel on “Expanding the Possible with Next-Generation Cell Therapies”
GAITHERSBURG, Md., Jan. 18, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Scott Carmer, Chief Executive Officer, will participate in the LLS TAP panel discussion entitled ...
-
Genenta Files Annual Report on Form 20-F for Fiscal Year 2021
Genenta Science S.p.A. (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, today announced it filed its annual report on Form 20-F for the fiscal year ended December 31, 2021 with the Securities and Exchange Commission ("SEC") on May 2, 2022. The annual report can be accessed on the Company's ...
-
NexImmune Announces Preliminary Phase 1/2 NEXI-002 Results in Patients with Multiple Myeloma
GAITHERSBURG, Md., Dec. 12, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced preliminary Phase 1/2 results from an ongoing study of NEXI-002, a patient-derived multi-antigen-specific ...
-
DermBiont Raises $28 Million and Acquires Chromaderm to Expand Targeted Topical Therapeutics in Development
BOSTON--(BUSINESS WIRE)-- DermBiont, Inc., a clinical-stage biotechnology company developing targeted topical therapeutics that address the root causes of skin diseases, announced today that it has raised a $28 million Series A2 financing in parallel with the acquisition of clinical-stage biotechnology company Chromaderm, which is developing a topical inhibitor of melanin production as a ...
-
CohBar to Announce 2022 First Quarter Financial Results and Provide Business Update on May 16, 2022
Company to host conference call and webcast at 5:00 p.m. ET MENLO PARK, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today that the company will release ...
By CohBar, Inc.
-
Cabaletta Bio Announces Presentation of Preclinical Data Supporting PLA2R-CAART as a Potential Precision Therapy for Antigen-Specific B Cell Depletion in PLA2R Membranous Nephropathy at ASN Kidney Week 2021
PHILADELPHIA, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that data from in vitro studies supporting the early preclinical validation of PLA2R-Chimeric AutoAntibody Receptor T (CAART) cell ...
-
Evaxion Biotech Closes its U.S. Initial Public Offering of American Depositary Shares
Evaxion Biotech, a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today the closing of its initial public offering of 3,000,000 American Depositary Shares (“ADSs”) at a public offering price of $10.00 per ADS. The gross proceeds from the offering, before ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you